article · Journal of Antimicrobial Chemotherapy

High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana

Ontlametse T. Bareng
Rosemary Musonda
Tony Chebani
Dorcas Maruapula
Irene Gobe
Roger Shapiro
Shahin Lockman
Modisa S. Motswaledi
Mpaphi B. Mbulawa
Natasha O. Moraka
Boitumelo Zuze
Charity Ralegoreng
Catherine K. Koofhethile
Joseph Makhema
Kedumetse Seru
Wonderful T. Choga
Sikhulile Moyo
Patrick Mokgethi
Patience Montshosi
Goitseone Martha Lemogang
Judith Nawa
Lindani Bochena
Gaonyadiwe Muzanywa
Thembinkosi M Shadreck
Simani Gaseitsiwe

20243 citationsOpen accessUniversity of Botswana

Abstract

A high but similar prevalence of any DRMs was observed among individuals with LLV and those with VF on dolutegravir-based therapy. Monitoring DRMs in individuals with detectable VL is crucial for preserving dolutegravir-based ART.

Research topics

HIV/AIDS drug development and treatment
HIV/AIDS Research and Interventions
HIV Research and Treatment

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/jac/dkae472

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.